The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞

The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis. In clinical trials, ezetimibe plus simvastatin produces greater LDL-cholesterol reductions than does monotherapy. The molecular me...

Full description

Bibliographic Details
Main Authors: Dawn E. Telford, Brian G. Sutherland, Jane Y. Edwards, Joseph D. Andrews, P. Hugh R. Barrett, Murray W. Huff
Format: Article
Language:English
Published: Elsevier 2007-03-01
Series:Journal of Lipid Research
Subjects:
cholesterol absorption
lipoproteins
apolipoprotein B kinetics
gene expression
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520432456

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520432456

Similar Items